These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 27858572

  • 1. Correlation between GH and IGF-1 during treatment for acromegaly.
    Oldfield EH, Jane JA, Thorner MO, Pledger CL, Sheehan JP, Vance ML.
    J Neurosurg; 2017 Jun; 126(6):1959-1966. PubMed ID: 27858572
    [Abstract] [Full Text] [Related]

  • 2. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S, Li Y, Guo X, Gao L, Lian W, Yao Y, Feng M, Bao X, Wang R, Xing B.
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [Abstract] [Full Text] [Related]

  • 3. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM, Loureiro RA, Parkinson C, Monson JP, Besser GM, Trainer PJ.
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [Abstract] [Full Text] [Related]

  • 4. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL, Mercado M, Sosa E, Lizama O, Guinto G, Lopez-Felix B, Garcia O, Hernández I, Ovalle A, Mendoza V.
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [Abstract] [Full Text] [Related]

  • 5. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [Abstract] [Full Text] [Related]

  • 6. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
    Skjaerbaek C, Frystyk J, Kaal A, Laursen T, Møller J, Weeke J, Jørgensen JO, Sandahl Christiansen J, Orskov H.
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
    Yan JL, Chang CN, Chuang CC, Hsu PW, Lin JD, Wei KC, Lee ST, Tseng JK, Pai PC, Chen YL.
    J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
    [Abstract] [Full Text] [Related]

  • 15. Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly.
    Valdemarsson S, Ljunggren S, Bramnert M, Norrhamn O, Nordström CH.
    J Intern Med; 2000 Jun; 247(6):640-50. PubMed ID: 10886485
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
    Brabant G.
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S15-20. PubMed ID: 12670296
    [Abstract] [Full Text] [Related]

  • 17. Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients.
    Uygur MM, Deyneli O, Yavuz DG.
    Growth Horm IGF Res; 2020 Dec; 55():101335. PubMed ID: 33190108
    [Abstract] [Full Text] [Related]

  • 18. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
    Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ.
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gender differences in serum GH and IGF-I levels and the GH response to dynamic tests in patients with acromegaly.
    Tanaka S, Fukuda I, Hizuka N, Takano K.
    Endocr J; 2010 Mar; 57(6):477-83. PubMed ID: 20203424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.